Showing posts with label cardiology. Show all posts
Showing posts with label cardiology. Show all posts

Monday, April 27, 2026

Why are primary cardiac cancers in mammals so rare? It is the rhytmic beating heart!

Good news! Cancer is history (soon)!

"Primary cardiac tumors—cancers that develop in the heart—are exceptionally rare. New research in Science suggests that this low incidence may be because the heart beats: The continuous mechanical stress seems to stymie cancer growth.

In one experiment, researchers introduced potent cancer-driving mutations into mice that often develop tumors. Cancers occurred elsewhere in the body, but not in the heart. The team next created a side-by-side comparison within the same animal by observing a native heart still pumping under normal strain, and a donor heart kept alive with blood flow but without having to do the mechanical work of pumping. Tumors grew preferentially in the lower-strain heart.

Researchers saw the same effect after injecting several types of human cancer cells directly into heart tissue: In beating hearts, many remained as only small clusters, while in less-strained hearts, they grew larger.

Further analyses showed that cancer cells in beating hearts had weirdly shaped nuclei, condensed chromatin, more tightly packed DNA, and lower activity in genes tied to growth and cell division.

The team also rhythmically stretched cancer cells in the lab and concluded that strain alone could reproduce some of these antigrowth features. ... the team is already testing prototype devices designed to rhythmically compress superficial tumors, in the hopes of recreating the heart’s protective mechanism. ... it may be possible to recreate the effect of mechanical strain pharmacologically, providing new avenues for cancer treatments."

"... The rhythmic beating of the heart may play an unexpected role in protecting it from cancer. An international study ... demonstrates that the mechanical forces generated by cardiac contraction can significantly slow tumour growth in both mouse and human hearts. ..."

From the abstract (Perspective):
"Heart cancer is very rare in mammals. Moreover, the healthy adult heart does not regenerate. Human heart cells (cardiomyocytes) renew at an ~1% rate per year. The high mechanical load placed on cardiac tissue, which must overcome strong resistance to pump blood to all body organs, has been proposed to inhibit cardiomyocyte proliferation. Indeed, reducing the mechanical load on the heart promotes the expression of cell cycle markers in cardiomyocytes of patients whose hearts were unloaded by a ventricular assist device. ... report that the constant mechanical load to which cardiac tissue is subjected also inhibits the proliferation of cancer cells in the heart."

From the editor's summary and abstract:
"Editor’s summary
It is very rare for cancer to either form in or metastasize to the heart, suggesting that there is something that inhibits cancer growth in the cardiac microenvironment.
A key potential explanation is mechanical load. Ciucci et al. tested this idea by introducing cancer cells into rodent hearts and then in vitro engineering cardiac models with or without normal mechanical load.
They also compared human tissue samples from rare cardiac metastases and corresponding extracardiac tumors. The authors determined that increased mechanical load promoted Nesprin-2 signaling, which then led to changes in chromatin compaction and histone methylation, resulting in the suppression of cancer growth  ...

Structured Abstract
INTRODUCTION
The heart is rarely affected by cancer; both primary cardiac tumors and metastases are uncommon despite the high vascularization of the myocardium. The mechanisms underlying this resistance remain unclear.

RATIONALE
Mechanical load has been proposed as a major mechanism halting cardiomyocyte proliferation early after birth, thus limiting the regenerative potential of the adult mammalian heart. We hypothesized that it could similarly hamper the proliferation of cancer cells in the heart.

RESULTS
We first used an in vivo genetic model of cancer in mice, in which Cre-mediated recombination results in the overexpression of mutated K-Ras and deletion of p53, to confirm that the heart resists oncogenic events. Despite a comparable extent of recombination in liver, heart, and skeletal muscle, multiple cancers arose at different anatomical sites but never in the heart.
In addition, we set up a mouse model of heterotopic heart transplantation to mechanically unload the heart in vivo. In this model, the aorta and pulmonary artery of the transplanted heart are surgically connected with the carotid artery and external jugular vein of the recipient animal, respectively, thereby restoring perfusion in the absence of mechanical load within the left ventricle. In parallel, we used engineered heart tissues in which mechanical load can be controlled at will.
In these models, mechanical load inhibited, whereas tissue unloading promoted the proliferation of lung adenocarcinoma, colon carcinoma, and melanoma cells within the myocardium.
To investigate the mechanisms underlying these effects, we used spatial transcriptomics to analyze samples of human cancers that gave rise to both cardiac and extracardiac metastases. We found that cardiac metastases shared a common transcriptional profile, independent from the origin of the primary tumor. Among the most up-regulated genes in cardiac metastases were histone demethylases. Consistently, cardiac metastases showed reduced histone 3 lysine 9 trimethylation and reduced chromatin compaction. Similar findings were observed in our experimental models of cardiac load modulation in which chromatin accessibility and histone methylation were altered at sites controlling cancer cell proliferation, as determined by single-nuclei assay for transposase-accessible chromatin with sequencing and chromatin immunoprecipitation sequencing. Nesprin-2, a protein known to mediate mechanotransduction from the cytoplasm to the nucleus, emerged as a key molecule sensing mechanical forces operating in beating hearts and translating them into reduced cell proliferation.
Silencing of Nesprin-2 in lung cancer cells prior to their implantation in the heart in vivo restored the capacity of the cells to proliferate in the presence of physiological mechanical load, resulting in the formation of large tumors.

CONCLUSION
Collectively, these results shed light on the role of mechanical forces in protecting the heart from cancer and may pave the way to cancer therapies based on mechanical stimulation."

ScienceAdviser

Heartbeat’s Mechanical Force Found to Suppress Tumour Growth (original news release)

The heart puts pressure on cancer growth (Perspective, no public access) "Mechanical forces in the heart prevent tumor expansion in mice"

Sunday, December 28, 2025

Doctors placed a stent in the heart of a fetus still inside the womb diagnosed with a rare and severe heart defect

Amazing stuff!

"Lauren and Alex Klingsporn were shocked by the news that their unborn son, Brooks, would need a series of surgeries after he was born to fix a rare and severe heart defect.

Brooks’ situation became even more desperate when doctors learned of another problem that was causing lung damage, making it unlikely he’d be healthy enough for the surgeries after birth. Babies born with Brooks’ condition have almost no chance of survival.

So, Texas Children’s Hospital tried something that sounds like science fiction. Doctors placed a stent in Brooks’ heart while he was still in the womb, a complex, high-risk procedure the hospital has performed only about 30 times over the past decade. ..."

"... Fetal cardiac intervention is complex surgery that is performed in the hospital. The mother and fetus are sedated, and an incision is made in the mother’s abdomen, similar to that for a cesarean section. An incision is made in her uterus, exposing the fetus. Guided by ultrasound images, a specialized needle is inserted into the heart of the fetus. A tiny tube, or catheter, with a balloon attached to it is introduced into the heart. The balloon is inflated to expand the valve and allow blood to flow. After the procedure, the fetus is returned to the mother’s uterus. Amniotic fluid is replaced, and the uterus and abdomen are closed. ..."

Texas Children's novel, in-utero surgery saved baby with rare defect

Thursday, December 18, 2025

Love is good for the heart: Fostering healthier relationships could improve cardiac rehabilitation

It is always refreshing when science confirms the obvious! As if we all did not know that already!

Perhaps the key takeaway is that science and medicine have long neglected to research healthy, intimate or close human relationships and their effects on one's health. A subject too complicated, revealing, too personally close and emotional for scientists, I bet! 😊

Maybe doctors need more marriage/couple partnership consultation training and education? 😊

"Heart disease is the leading cause of death worldwide. Most cardiac rehabilitation programs seeking to shift this worrisome statistic focus on individuals, in the hopes that people can learn how to lower their risk and improve their cardiac health. But according to a new review, those programs all too often overlook an important component of heart health. “Considering the well-established literature highlighting that relationship quality impacts heart health, it is surprising that such a limited number of studies have targeted relationship quality in their interventions,” said co-author Heather Tulloch in a statement.

Previous studies have found that single people (whether never married, divorced, or widowed) are over 40% more likely to die from a heart attack than married people. So, the team wondered: Are programs that include a person’s partner effective at promoting heart-healthy behaviors? To find out, they examined 16 trials that involved couples.
In more than three-quarters of them, the answer was yes: involving intimate partners led to heart-healthy behavioral changes—even though all but two programs lacked a foundation in relationship science, which likely undermined their effectiveness. ..."

From the abstract:
"Social relationships, particularly the quality of intimate partnerships, play a significant role in cardiovascular outcomes and recovery. While most cardiac care focuses on individual patients, couples-based approaches may offer additional benefits to support behavior change and emotional adjustment. However, their effectiveness remains unclear.
This review evaluates the effectiveness of couples-based interventions on modifiable cardiovascular risk factors, cardiac outcomes, mental health, and relationship quality (RQ) in adults with diagnosed heart disease and their partners. We reviewed randomized controlled trials (RCTs) published until May 29, 2025, involving cardiac patients and their partners. Twelve RCTs (16 articles) met inclusion criteria, involving 1,444 patient-partner dyads.
Most interventions were nurse-led and behaviorally focused. Select cardiovascular outcomes (e.g., lipid profiles, healthcare utilization) improved, though findings were inconsistent.
Health behavior improvements were reported in 77% of studies, while mental health outcomes showed mixed effects.
None of the three studies assessing RQ found significant improvements. With their primary focus on behaviour change, these couples-based interventions for patients with cardiovascular disease and their partners appear effective for improving health behaviors, with mixed evidence for cardiac and mental health outcomes.
Future research including emotional and relational components, underserved populations, validated relationship measures, and that assesses outcomes in both patients and partners are needed. In cardiac rehabilitation, a stepped care model may help tailor interventions to couples’ specific needs."

ScienceAdviser

Can intimate relationships affect your heart? New study says ‘yes’ "An article in the Canadian Journal of Cardiology highlights the need to focus on emotional and relational factors to improve recovery and well-being for cardiac patients and their partners"



What a busy graphical summary! Human relationships, it's complicated!


Sunday, December 07, 2025

Delivering defibrillators by drone to real 911 calls

Good news! This is only the beginning of what can be done with drones!

Time to renew my first aid training? 😊

"... "There’s only really 10 minutes to help that person survive" ...

The 911 dispatcher coordinates with a drone pilot to fly the drone to the location of the cardiac arrest. Stark said that in their research they have been able to strategically position drones to lower response times from an average of 6 to 7 minutes to less than 4 minutes. ..."

"In Clemmons, North Carolina, Duke University researchers are sending defibrillators by drone to real 911 calls, the first program of its kind in the US. The drones’ median response time is 2 to 3 minutes faster than an ambulance, giving bystanders a chance to start lifesaving treatment sooner."

Doomslayer: Progress Roundup - by Malcolm Cochran







Wednesday, November 05, 2025

A new programmable patch attached to the heart after heart attack to promote tissue healing

Amazing stuff! To attach a patch to the heart!

"MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help promote healing and regeneration of cardiac tissue.

The new patch is designed to carry several different drugs that can be released at different times, on a pre-programmed schedule. In a study of rats, the researchers showed that this treatment reduced the amount of damaged heart tissue by 50 percent and significantly improved cardiac function. ..."

From the highlights and abstract:
"Highlights
Programmable multi-phasic release via microparticles in a hydrogel patch
• Strong mechanics, biocompatibility, and storage stability for clinical use
• TIMED improves survival, restores function, and reduces injury in vitro and in vivo
•Modular, localized sequential therapy adaptable to broad clinical contexts

Summary
Myocardial infarction (MI) is a major global health challenge. Surgical interventions address the acute phase but often fail to support long-term recovery. Sequential post-operative drug delivery offers promise but is constrained by release methods.
Here, we developed TIMED (temporal intervention with microparticle encapsulation and delivery), a polymeric device enabling programmed sequential release through spatially patterned microparticles in a tough hydrogel matrix. TIMED demonstrated excellent mechanical performance and biocompatibility for long-term implantation and retained strong stability after storage.
A sequential dosing regimen aligned with the innate post-MI response was first validated in hiPSC-derived cardiac tissues, where it enhanced cell viability and vascularization while reducing collagen deposition.
In vivo, delivery via the TIMED improved survival, reduced injury markers and infarct size, and enhanced cardiac output, outperforming equivalent i.v. dosing. This work establishes a first-of-its-kind cardiac implantable polymeric platform with modular sequential release and provides a framework for programmed multi-dosing across diverse applications."

A new patch could help to heal the heart | MIT News | Massachusetts Institute of Technology "MIT engineers developed a programmable drug-delivery patch that can promote tissue healing and blood vessel regrowth following a heart attack."


Graphical abstract


Thursday, August 28, 2025

Nanoparticles detect and reduce artery plaques

Good news!

"A new generation of “theranostic” nanoparticles has been shown to both detect and reduce plaques in the arteries. Nanoparticles absorbed by immune cells in the arteries, where they work to lower inflammation and draw out harmful cholesterol, offer an entirely new way of not just diagnosing but fighting heart disease without drugs. ..."

"... The study used advanced imaging techniques to track the movement of the nanoparticles in pre-clinical models of heart disease. They were able to target inflamed plaques and significantly reduce both plaque size and inflammation.

"One of the key challenges in treating atherosclerosis is that inflammation fuels plaque build-up, creating a vicious cycle. Our nanoparticles help break that cycle, which could lead to better long-term outcomes for patients,” ...

In addition to their ability to shrink plaques, the nanoparticles have powerful imaging capabilities that allow for earlier detection of arterial disease. This could help cardiologists identify at-risk patients sooner and intervene with treatments before complications arise. ..."

From the highlights and abstract:
"Highlights
• Atherosclerosis is the deposition of fatty plaques in arteries and the main cause of heart attacks.
• Strategies to improve detection and reduce atherosclerotic plaques are needed.
Multifunctional porphyrin-lipid nanoparticles (Por-NPs) have diagnostic and therapeutic properties.
• Por-NPs are internalized by macrophages and track to atherosclerotic plaques, visualized using multiple imaging modalities.
• Por-NPs exert atheroprotective effects in vitro in macrophages. They suppress inflammation and promote cholesterol efflux.
• Por-NPs exhibit therapeutic effects in two murine models of atherosclerosis and significantly reduce plaque size.

Abstract
Background
Porphyrin-lipid nanoparticles (Por-NPs) have unrealized potential for atherosclerosis. Por-NPs incorporate porphyrin-lipid which permits fluorescence imaging and chelates Copper-64 (64Cu) for positron emission tomography (PET) imaging. Their outer shell contains a short peptide ‘R4F’ that enables macrophage targeting and therapeutic effects. Accordingly, this study investigates the simultaneous diagnostic and therapeutic properties of Por-NPs in atherosclerosis.

Results
In vitro, Por-NPs were found to be internalized by immortalised bone marrow-derived macrophages (iBMDMs), visualized via fluorescence microscopy and flow cytometry.
Por-NPs also increased cholesterol efflux from [3H]-cholesterol-loaded iBMDMs, (49 %, P < 0.05).
Incubation of iBMDMs with Por-NPs reduced mRNA levels of inflammatory mediators Il1b (88 %), Il18 (54 %) Ccl5 (75 %) and Ccl17 (92 %), and protein secretion of IL-1β (69 %), CCL5 (82 %) and CCL17 (94 %), P < 0.05. Por-NPs suppressed inflammasome components Nlrp3 (69 %) and Asc (36 %), P < 0.05. Studies using siRNA deletion of SR-B1 and methyl-β-cyclodextrin, revealed the anti-inflammatory properties of Por-NPs were independent of SR-B1 and cholesterol efflux. However, Por-NPs suppressed activation of inflammatory transcription factor NF-κB (53 %, P < 0.05).
In vivo, in Apoe−/− mice, serial non-invasive PET imaging showed 64Cu-labelled Por-NPs localised in hearts and detected increases in plaque size longitudinally with high-cholesterol diet. Por-NP fluorescence was visualized in aortic sinus plaques, co-localised with CD68+ macrophages, and by fluorescence IVIS imaging in aortic arch plaque.
In two murine models, Por-NP-treated mice had smaller early-stage (22 %) and unstable plaques (52 %). Por-NP-treated mice had fewer circulating (32 %) and aortic (81 %) monocytes, and lower mRNA levels of aortic arch Rela (26 %) and Nfkb1 (27 %), P < 0.05.

Conclusions
Por-NPs detect plaques using multiple imaging modalities and exhibit atheroprotective effects, presenting as novel nanoscale theranostics for atherosclerosis."

Nanoparticles detect and reduce artery plaques

Nanoparticles engineered to suck the plaque out of arteries (original news release) "Researchers at SAHMRI are using specially designed nanoparticles to detect and help treat plaque build-up in arteries for the first time, offering a potential new approach to diagnosing and managing heart disease."



Graphical abstract


Sunday, April 27, 2025

Multi-sensor stethoscope-like flexible, handheld device offers improved heart valve disease detection and more even for untrained users

Good news! The good old stethoscope is getting an upgrade! 😊

"Valvular heart disease (VHD) is a potentially fatal condition, yet it's difficult to diagnose with a regular stethoscope. A possibly life-saving new multi-sensor stethoscope is claimed to be much better at the job, with the added benefit that it can be used by just about anyone. ...

the flexible handheld device is about the size and shape of a drink coaster, and it incorporates not one but six vibration-detecting piezoelectric sensors. ...

Those sensors are separated from one another by a vibration-absorbing silicone gel, allowing each one to operate completely independent of the others. Signal-quality-assessing algorithms automatically select the sensors that are receiving the best readings, ignoring those that lack sufficient diagnostic quality.

This multi-sensor design reportedly makes the device much better at detecting the telltale heart sounds associated with VHD, enough so that it can be used overtop of clothing by people with little training – possibly even by the patients themselves. ..."

"The researchers ... developed a device that makes it easy for people with or without medical training to record heart sounds accurately. Unlike a stethoscope, the device works well even if it’s not placed precisely on the chest: its larger, flexible sensing area helps capture clearer heart sounds than traditional stethoscopes.

The device can also be used over clothing, making it more comfortable for patients – especially women – during routine check-ups or community heart health screening programmes. ..."

From the abstract:
"Heart valve disease has a large and growing burden, with a prognosis worse than many cancers. Screening with a traditional stethoscope is underutilised, often inaccurate even in skilled hands, and requires time-consuming, intimate examinations.
Here, we present a handheld device to enable untrained users to record high-quality heart sounds without requiring patients to undress.
The device incorporates multiple high-sensitivity sensors embedded in a flexible substrate, placed at key chest locations by the user.
To address challenges from localised heart sound vibrations and noise interference, we developed time-frequency signal quality algorithms that automatically select the best sensor in the device and reject recordings with insufficient diagnostic quality.
A validation study demonstrates the device's effectiveness across a diverse range of body types, with multiple sensors significantly increasing the likelihood of a successful recording. The device has the potential to enable accurate, accessible, low-cost heart disease screening."

Multi-sensor stethoscope offers improved heart valve disease detection

Handheld device could transform heart disease screening (original news release) "Researchers have developed a handheld device that could potentially replace stethoscopes as a tool for detecting certain types of heart disease."




Fig. 1 Design and example usage of sensor prototype. a, Exploded schematic of full sensor prototype. 


Wednesday, March 12, 2025

World's First: Man Lives 100 Days with Artificial Titanium Heart with Palki Sharma

Good news! My heart is jumping now!

Australian man survives 100 days with artificial heart in world-first success

Good news!

"... The Australian researchers and doctors behind the operation announced on Wednesday that the implant had been an “unmitigated clinical success” after the man lived with the device for more than 100 days before receiving a donor heart transplant in early March.

The BiVACOR total artificial heart, invented by Queensland-born Dr Daniel Timms, is the world’s first implantable rotary blood pump that can act as a complete replacement for a human heart, using magnetic levitation technology to replicate the natural blood flow of a healthy heart. ..."

Australian man survives 100 days with artificial heart in world-first success | Health | The Guardian "Sydney surgeons ‘enormously proud’ after patient in his 40s receives the Australian-designed implant designed as a bridge before donor heart"

Saturday, February 22, 2025

Künstliche Intelligenz enthüllt geheime Warnsignale im EKG

Gute Nachrichten!

"Ein interdisziplinäres Team des Deutschen Zentrums für Herz-Kreislauf-Forschung (DZHK) hat in einer langfristigen Bevölkerungsstudie herausgefunden, dass künstliche Intelligenz (KI) in der Lage ist, das biologische Alter des Herzens aus EKG-Daten zu bestimmen. Damit einher geht die Erkenntnis, dass die KI frühzeitig vor erhöhten Herz-Kreislauf-Risiken warnen kann. ...

In der aktuellen Studie wurde eine KI darauf trainiert, das „EKG-Alter“ des Herzens im Vergleich zum chronologischen Herzalter zu schätzen. Bestehen hierbei größere Differenzen, könnte das darauf hinweisen, dass sich bereits schädliche Prozesse entwickeln, noch bevor klassische Risikofaktoren auffallen. Die KI weiß daher frühzeitig, wenn sich das kardiovaskuläre Risiko erhöht. ..."

From the abstract:
"Aging affects the 12-lead electrocardiogram (ECG) and correlates with cardiovascular disease (CVD). AI-ECG models estimate aging effects as a novel biomarker but have only been evaluated on single ECGs—without utilizing longitudinal data.
We validated an AI-ECG model, originally trained on Brazilian data, using a German cohort with over 20 years of follow-up, demonstrating similar performance (r2 = 0.70) to the original study (0.71).
Incorporating longitudinal ECGs revealed a stronger association with cardiovascular risk, increasing the hazard ratio for mortality from 1.43 to 1.65. Moreover, aging effects were associated with higher odds ratios for atrial fibrillation, heart failure, and mortality. Using explainable AI methods revealed that the model aligns with clinical knowledge by focusing on ECG features known to reflect aging. Our study suggests that aging effects in longitudinal ECGs can be applied on population level as a novel biomarker to identify patients at risk early."

Künstliche Intelligenz enthüllt geheime Warnsignale im EKG  "Künstliche Intelligenz erkennt frühzeitig allein aus EKG-Daten, ob das Risiko für eine Herz-Kreislauf erhöht ist. Die KI schätzt dabei das EKG-Alter des Herzens ab."

Künstliche Intelligenz erkennt Herzalterung im EKG und warnt frühzeitig vor Herz-Kreislauf-Risiken (Originale Pressemitteilung) "Ein interdisziplinäres Forschungsteam des Deutschen Zentrums für Herz-Kreislauf-Forschung (DZHK) hat erstmals in einer langfristigen Bevölkerungsstudie nachgewiesen, dass künstliche Intelligenz (KI) das biologische Altern des Herzens anhand von EKG-Daten erfassen und mit einem erhöhten kardiovaskulären Risiko in Verbindung bringen kann. Die Ergebnisse der Studie wurden in der Fachzeitschrift npj Digital Medicine veröffentlicht."



Fig. 2: Kaplan–Meier survival estimates based on the gap between predicted ECG-age and chronological age.


Thursday, February 20, 2025

Can deep learning transform heart failure prevention? A rhetorical question!

Good news!

"... a noninvasive deep learning approach that analyzes electrocardiogram (ECG) signals to accurately predict a patient’s risk of developing heart failure. In a clinical trial, the model showed results with accuracy comparable to gold-standard but more-invasive procedures, giving hope to those at risk of heart failure.
The condition has recently seen a sharp increase in mortality, particularly among young adults, likely due to the growing prevalence of obesity and diabetes. ...

The current gold standard for measuring left atrial pressure is right heart catheterization (RHC), an invasive procedure that requires a thin tube (the catheter) attached to a pressure transmitter to be inserted into the right heart and pulmonary arteries. Physicians often prefer to assess risk noninvasively before resorting to RHC, by examining the patient’s weight, blood pressure, and heart rate.

Cardiac Hemodynamic AI monitoring System (CHAIS), a deep neural network capable of analyzing ECG data from a single lead — in other words, the patient only needs to have a single adhesive, commercially-available patch on their chest that they can wear outside of the hospital, untethered to a machine. ..."

From the abstract:
"Background
The ability to non-invasively measure left atrial pressure would facilitate the identification of patients at risk of pulmonary congestion and guide proactive heart failure care. Wearable cardiac monitors, which record single-lead electrocardiogram data, provide information that can be leveraged to infer left atrial pressures.

Methods
We developed a deep neural network using single-lead electrocardiogram data to determine when the left atrial pressure is elevated. The model was developed and internally evaluated using a cohort of 6739 samples from the Massachusetts General Hospital (MGH) and externally validated on a cohort of 4620 samples from a second institution. We then evaluated model on patch-monitor electrocardiographic data on a small prospective cohort.

Results
The model achieves an area under the receiver operating characteristic curve of 0.80 for detecting elevated left atrial pressures on an internal holdout dataset from MGH and 0.76 on an external validation set from a second institution.
A further prospective dataset was obtained using single-lead electrocardiogram data with a patch-monitor from patients who underwent right heart catheterization at MGH. Evaluation of the model on this dataset yielded an area under the receiver operating characteristic curve of 0.875 for identifying elevated left atrial pressures for electrocardiogram signals acquired close to the time of the right heart catheterization procedure.

Conclusions
These results demonstrate the utility and the potential of ambulatory cardiac hemodynamic monitoring with electrocardiogram patch-monitors."

Can deep learning transform heart failure prevention? | MIT News | Massachusetts Institute of Technology "A deep neural network called CHAIS may soon replace invasive procedures like catheterization as the new gold standard for monitoring heart health."



Fig. 1: Model development and evaluation.


Tuesday, December 31, 2024

Gene therapy shows promise for reversing heart failure

Good news!

"... The new gene therapy ... prevented heart failure (HF) from worsening and even improved some key measures of heart function in pig models. ..."

"A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model, according to new research ... The therapy increases the amount of blood the heart can pump and dramatically improves survival, in what the study calls “an unprecedented recovery of cardiac function.”

Currently, heart failure is irreversible. In the absence of a heart transplant, most medical treatments aim to reduce the stress on the heart and slow the progression of the often-deadly disease. But if the gene therapy shows similar results in future clinical trials, it could help heal the hearts of the one in four people alive today who will eventually develop heart failure. ..."

From the abstract:
"Heart failure (HF) is a major cause of mortality and morbidity worldwide, yet with limited therapeutic options. Cardiac bridging integrator 1 (cBIN1), a cardiomyocyte transverse-tubule (t-tubule) scaffolding protein which organizes the calcium handling machinery, is transcriptionally reduced in HF and can be recovered for functional rescue in mice.
Here we report that in human patients with HF with reduced ejection fraction (HFrEF), left ventricular cBIN1 levels linearly correlate with organ-level ventricular remodeling such as diastolic diameter. Using a minipig model of right ventricular tachypacing-induced non-ischemic dilated cardiomyopathy and chronic HFrEF, we identified that a single intravenous low dose (6 × 1011 vg/kg) of adeno associated virus 9 (AAV9)-packaged cBIN1 improves ventricular remodeling and performance, reduces pulmonary and systemic fluid retention, and increases survival in HFrEF minipigs. In cardiomyocytes, AAV9-cBIN1 restores t-tubule organization and ultrastructure in failing cardiomyocytes. In conclusion, AAV9-based cBIN1 gene therapy rescues non-ischemic HFrEF with reduced mortality in minipigs."

Gene therapy shows promise for reversing heart failure



Fig. 2: AAV9 transduced cBIN1 in myocardium rescues survival rates in minipigs with RVP-induced non-ischemic HFrEF.


Friday, October 25, 2024

Two, almost simultaneously published, very promising, but different studies about heart repair after heart attack by UCLA

Good news! 

About the first study:

"Key takeaways
  • An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance tissue repair in the heart following a heart attack. 
  • Scientists ... blocked a protein called ENPP1, which increases inflammation and scar tissue formation that exacerbate heart damage. 
  • One dose of the antibody was shown to reduce scar tissue formation in mice and improve cardiac function.
...
The new therapeutic approach aims to improve heart function after a heart attack by blocking a protein called ENPP1, which is responsible for increasing the inflammation and scar tissue formation that exacerbate heart damage. The findings ... could represent a major advance in post-heart attack treatment. ...

The researchers found that a single dose of the antibody significantly enhanced heart repair in mice, preventing extensive tissue damage, reducing scar tissue formation and improving cardiac function. Four weeks after a simulated heart attack, only 5% of animals that received the antibody developed severe heart failure, compared with 52% of animals in the control group. ...

Initial findings from preclinical studies also show that the antibody therapy safely decreased scar tissue formation without increasing the risk of heart rupture — a common concern after a heart attack. ..."

From the highlights and abstract of the first study:
"Highlights
• ENPP1 is known to initiate an aberrant metabolic cascade after myocardial infarction
• A humanized monoclonal antibody targeting human ENPP1 is engineered (hENPP1mAb)
• Systemic administration of hENPP1mAb rescues post-infarct metabolic defects
• In humanized mice, a single dose of hENPP1mAb rescues post-infarct heart function
Summary
Myocardial infarction (MI) results in aberrant cardiac metabolism, but no therapeutics have been designed to target cardiac metabolism to enhance heart repair. We engineer a humanized monoclonal antibody against the ectonucleotidase ENPP1 (hENPP1mAb) that targets metabolic crosstalk in the infarcted heart. In mice expressing human ENPP1, systemic administration of hENPP1mAb metabolically reprograms myocytes and non-myocytes and leads to a significant rescue of post-MI heart dysfunction. Using metabolomics, single-nuclear transcriptomics, and cellular respiration studies, we show that the administration of the hENPP1mAb induces organ-wide metabolic and transcriptional reprogramming of the heart that enhances myocyte cellular respiration and decreases cell death and fibrosis in the infarcted heart. Biodistribution and safety studies showed specific organ-wide distribution with the antibody being well tolerated. In humanized animals, with drug clearance kinetics similar to humans, we demonstrate that a single “shot” of the hENPP1mAb after MI is sufficient to rescue cardiac dysfunction."

About the second study:

"FINDINGS

UCLA scientists have identified the protein GPNMB as a critical regulator in the heart’s healing process after a heart attack. 

Using animal models, they demonstrate that bone marrow-derived immune cells called macrophages secrete GPNMB, which binds to the receptor GPR39, promoting heart repair. These findings offer a new understanding of how the heart heals itself and could lead to new treatments aimed at improving heart function and preventing the progression to heart failure. ...

Previous clinical studies have indicated that GPNMB, or glycoprotein non-metastatic melanoma protein B, has been strongly associated with cardiovascular outcomes of individuals with heart failure. What was not clear, however, was if lacking the protein was directly responsible for the development of heart failure after a heart attack. This important distinction — whether GPNMB is just an associated biomarker or one that plays a causal role — determines if the protein can be considered a therapeutic target for future studies. ...

Utilizing mouse models, the researchers first established that GPNMB is not natively expressed by the heart itself but is produced by inflammatory cells originating from the bone marrow. After a heart attack, these macrophages travel to the site of injury in the heart, where they express GPNMB. 

The team conducted gene knockouts — inactivating the GPNMB gene — and bone marrow transplants and observed that mice lacking the GPNMB gene exhibited dramatically worse outcomes after a heart attack, including a higher incidence of heart rupture, a fatal complication also seen in human heart failure patients. Conversely, mice with normal GPNMB expression that were given an additional dose of circulating GPNMB protein showed improved heart function and reduced scarring. Four weeks after a simulated heart attack, 67% of the animals lacking the GPNMB gene exhibited severe fibrosis, or scarring, compared with only 8% of animals in the control group. ..."

From the abstract:
"Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type I transmembrane protein initially identified in nonmetastatic melanomas and has been associated with human heart failure; however, its role in cardiac injury and function remains unclear. Here we show that GPNMB expression is elevated in failing human and mouse hearts after myocardial infarction (MI). Lineage tracing and bone-marrow transplantation reveal that bone-marrow-derived macrophages are the main source of GPNMB in injured hearts. Using genetic loss-of-function models, we demonstrate that GPNMB deficiency leads to increased mortality, cardiac rupture and rapid post-MI left ventricular dysfunction. Conversely, increasing circulating GPNMB levels through viral delivery improves heart function after MI. Single-cell transcriptomics show that GPNMB enhances myocyte contraction and reduces fibroblast activation. Additionally, we identified GPR39 as a receptor for circulating GPNMB, with its absence negating the beneficial effects. These findings highlight a pivotal role of macrophage-derived GPNMBs in post-MI cardiac repair through GPR39 signaling."

New therapy could enhance heart repair after heart attack | UCLA "New single-dose therapy shows promise in enhancing repair after heart attacks in preclinical models"


UCLA researchers uncover novel role of protein GPNMB in heart repair "New study highlights a target for therapies to prevent heart failure after heart attacks"


ENPP1 is expressed in the region of scarring after injury to the heart. Cardiac muscle shown in red and ENPP1 in green demonstrates expression of ENPP1 in the region of scar formation.


Graphical abstract of first study


Friday, August 30, 2024

Injectable pacemaker regulates heartbeat for 5 days then dissolves

Amazing stuff! Almost mind blowing! Though, it has not yet been tested on humans.

"... It’s essentially a syringe with an ultrathin needle – thinner than a human hair – that injects a solution containing nanoparticles. When this comes into contact with tissue, it forms an electrically conductive polymer hydrogel.

The idea is that when needed, this can be injected into the chest of a patient with arrhythmia, where it forms a kind of electrode around the heart. The tiny pinprick site of the injection acts as a point of contact for an external device, such as a mobile phone, the team says. This allows ECG measurements to be taken, as well as stimulating the heart with low-power electricity to regulate the heartbeat. ..."

From the abstract:
"Without intervention, cardiac arrhythmias pose a risk of fatality. However, timely intervention can be challenging in environments where transporting a large, heavy defibrillator is impractical, or emergency surgery to implant cardiac stimulation devices is not feasible. Here, we introduce an injectable cardiac stimulator, a syringe loaded with a nanoparticle solution comprising a conductive polymer and a monomer that, upon injection, forms a conductive structure around the heart for cardiac stimulation. Following treatment, the electrode is cleared from the body, eliminating the need for surgical extraction. The mixture adheres to the beating heart in vivo without disrupting its normal rhythm. The electrofunctionalized injectable cardiac stimulator demonstrates a tissue-compatible Young’s modulus of 21 kPa and a high conductivity of 55 S/cm. The injected electrode facilitates electrocardiogram measurements, regulates heartbeat in vivo, and rectifies arrhythmia. Conductive functionality is maintained for five consecutive days, and no toxicity is observed at the organism, organ, or cellular levels."

Injectable pacemaker regulates heartbeat for 5 days then dissolves "A new injectable, temporary pacemaker could help correct a heart arrhythmia in an emergency. This nanoparticle gel can regulate the heart’s electrical signals for up to five days before dissolving harmlessly in the body."

Injectable heart stimulator for emergency situations (original news release) "By injecting a solution of nanoparticles around the heart, a temporary heart stimulator self-assembles, which can correct heart arrhythmia in emergency situations with the help of an external power source. After treatment, the electrode spontaneously disappears from the body. The study was conducted on animals."



In animal studies, researchers have developed an injectable cardiac stimulator for emergency situations. The illustration shows how the injectable heart stimulator is supposed to work when fully developed and tested.


Fig. 4: eBICS is resorbed after 7 days and can be applied to larger animals.


Thursday, August 29, 2024

Compensatory sleep can make up for sleep deprivation to reduce heart disease risk

Good news! If I remember correctly, then it was previously believed this was not possible!

"Sleep-deprived people who catch up on sleep over weekends may reduce their heart disease risk by a fifth, according to a British study of 90,000 people presented at the European Society of Cardiology Congress ..."

Global Health NOW: Rising Vax Misinformation; Mosquitoes Don’t Care About Political Boundaries; and The Real HouseWolves of Beverly Hills

Exploring cardiovascular health: lifestyle, economics, and disparities "Weekend compensatory sleep is associated with reduced risk of heart disease: a prospective UK Biobank-based cohort study"




Thursday, May 30, 2024

Mouse bone marrow records cardiac troubles indicating lasting immune memory leading to cardiovascular disease and other comorbidities

Good news! Amazing stuff!

"Heart failure rarely occurs in isolation. Patients with this condition are prone to recurring cardiac problems and frequently develop other conditions, such as kidney disease, that involve chronic inflammation. Now, experiments in mice suggest that this could be because cardiac stress causes lasting changes to cells in bone marrow, and this “memory” makes the heart and other organs more vulnerable to disease.

Changes in cardiac macrophages—immune cells that play a vital role in maintaining heart health—have previously been linked to heart failure, but researchers wondered if the stem cells that give rise to them also play a role in cardiovascular disease. To find out more, they extracted bone marrow from rodents with heart failure and transplanted it into healthy recipients. They found that when these blood stem cells matured into macrophages and settled in the recipient mice’s hearts, they tended to respond poorly to stress. As a result, mice that received these cells began to spontaneously develop heart problems and became susceptible to kidney and muscle damage.

The findings suggest that—at least in mice—bone marrow “serves as a hub for stress responses,” with blood stem cells carrying key “stress memories.” These memories, the researchers note, may be responsible for the comorbidities and repeated episodes of heart failure seen in human patients."

From the editor's summary and abstract:
"Editor’s summary
Heart failure (HF) is often associated with recurrence and the development of comorbidities, but the mechanisms driving multimorbidity in patients with HF are not fully understood. Using a mouse model of HF, Nakayama et al. found that transplantation of bone marrow from these mice spontaneously resulted in cardiac dysfunction in recipient mice. Mice transplanted with HF-experience bone marrow were also more vulnerable to kidney and skeletal muscle injury. HF reprogrammed hematopoietic stem cell differentiation and altered tissue macrophage homeostasis. Together, these finding demonstrate that the bone marrow can carry an innate immune memory of cardiac stress that may exacerbate HF and predispose other organs to pathology. ...
Abstract
Patients with heart failure (HF) often experience repeated acute decompensation and develop comorbidities such as chronic kidney disease and frailty syndrome. Although this suggests pathological interaction among comorbidities, the mechanisms linking them are poorly understood. Here, we identified alterations in hematopoietic stem cells (HSCs) as a critical driver of recurrent HF and associated comorbidities. Bone marrow transplantation from HF-experienced mice resulted in spontaneous cardiac dysfunction and fibrosis in recipient mice, as well as increased vulnerability to kidney and skeletal muscle insults. HF enhanced the capacity of HSCs to generate proinflammatory macrophages. In HF mice, global chromatin accessibility analysis and single-cell RNA-seq showed that transforming growth factor–β (TGF-β) signaling was suppressed in HSCs, which corresponded with repressed sympathetic nervous activity in bone marrow. Transplantation of bone marrow from mice in which TGF-β signaling was inhibited similarly exacerbated cardiac dysfunction. Collectively, these results suggest that cardiac stress modulates the epigenome of HSCs, which in turn alters their capacity to generate cardiac macrophage subpopulations. This change in HSCs may be a common driver of repeated HF events and comorbidity by serving as a key carrier of “stress memory.”"

ScienceAdvisor


Fig. 1. Transplantation of BM from TAC mice induces spontaneous cardiac dysfunction.


Saturday, April 13, 2024

App detects heart failure vibes via a smartphone's existing sensors

Good news! Your smartphone becomes your personal doctor! 

The song Staying alive by the Bee Gees with a whole new meaning ("I am going nowhere. Somebody help me")! 😊

"Detecting the first stages of heart failure could soon be as simple as placing a smartphone on a patient's chest. That's the conclusion of an ongoing study, which is aimed at developing an app for diagnosing the potentially lethal condition as early as possible. ..."

"... Gyrocardiography is a non-invasive technique for measuring cardiac vibrations on the chest. The smartphone's built-in motion sensors can detect and record these vibrations, including those that doctors cannot hear with a stethoscope. The method has been developed over the last 10 years by researchers at the University of Turku and CardioSignal. ..."

From the abstract:
"Abstract
Background
Heart failure (HF) is the leading cause of hospitalization in individuals over 65 years of age. Identifying noninvasive methods to detect HF may address the epidemic of HF. Seismocardiography which measures cardiac vibrations transmitted to the chest wall has recently emerged as a promising technology to detect HF.
Objectives
In this multicenter study, the authors examined whether seismocardiography using commercially available smartphones can differentiate control subjects from patients with stage C HF.
Methods
Both inpatients and outpatients with HF were enrolled from Finland and the United States. Inpatients with HF were assessed within 2 days of admission, and outpatients were assessed in the ambulatory setting. In a prespecified pooled data analysis, algorithms were derived using logistic regression and then validated using a bootstrap aggregation method.
Results
A total of 217 participants with HF (174 inpatients and 172 outpatients) and 786 control subjects from cardiovascular clinics were enrolled. The mean age of participants with acute HF was 64 ± 13 years, 64.9% were male, left ventricular ejection fraction was 39 ± 15%, and median N-terminal pro–B-type natriuretic peptide was 5,778 ng/L (Q1-Q3: 1,933-6,703). The majority (74%) of participants with HF had reduced EF, and 38% had atrial fibrillation. Across both HF cohorts, the algorithms had an area under the receiver operating characteristic curve of 0.95 with a sensitivity of 85%, specificity of 90%, and accuracy of 89% for the detection of HF, with a decision threshold of 0.5. The positive and negative likelihood ratios were 8.50 and 0.17, respectively. The accuracy of the algorithms was not significantly different in subgroups based on age, sex, body mass index, and atrial fibrillation.
Conclusions
Smartphone-based assessment of cardiac function using seismocardiography is feasible and differentiates patients with HF from control subjects with high diagnostic accuracy. ..."

App detects heart failure vibes via a smartphone's existing sensors

Researchers developed new method for detecting heart failure with a smartphone The new technology, which was created at the University of Turku and developed by the company CardioSignal, uses a smartphone to analyse heart movement and detect heart failure. The study involved five organisations from Finland and the United States.




Friday, April 12, 2024

Nasal spray can safely treat recurrent abnormal heart rhythms

Amazing stuff! What else can be treated through your nose? 😊 Snorting cocaine is not so healthy!

"A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms.  ..."

Nasal spray can safely treat recurrent abnormal heart rhythms | Cornell Chronicle